Less frequent dosing of bisphosphonates in osteoporosis: Focus on ibandronate

Current Medical Research and Opinion

Volumn 22, Issue 6, 2006, Pages 1101-1108

  Simonelli, Christine ^a,b   Burke, M Susan ^c  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adherence; Ibandronate; Mechanism of action; Osteoporosis

Indexed keywords

IBANDRONIC ACID;

BONE STRENGTH; CLINICAL PRACTICE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; MEDLINE; OSTEOPOROSIS; PUBLICATION; REVIEW;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; MEDLINE; OSTEOPOROSIS; PERIODICALS; RETROSPECTIVE STUDIES;

EID: 33745700042     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X104867     Document Type: Review

References (49)

1. National Institutes of Health. Osteoporosis prevention, diagnosis, and therapy. NIH consensus statement. 2000;17:1-45
2. National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass in our nation. 2002
3. Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120-6
4. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99
5. YoodRA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965-8
6. Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 2003;72:408 [abstract P-297]
7. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8
8. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87
9. Barrett J, Worth E, Bauss F, et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;44:951-65
10. Mersfelder T, Armitstead JA, Ivey MF, et al. A medication use evaluation of alendronate: compliance with administration guidelines. Pharm Pract Manage Q 1999;18:50-8
11. Lombas C, Hakim C, Zanchetta JR. Compliance with alendronate treatment in an osteoporosis clinic. J Bone Min Res 2001;15:S529 [abstract M406]
12. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
13. Ettinger M, Gallagher R, Amonkar M, et al. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum 2004;50:S513
14. US Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General, 2004
15. Marshall JK. The gastrointestinal tolerability and safety of oral bisphosphonates. Exp Opin Drug Saf 2002;1:71-8
16. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998;4:1377-82
17. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14:259-62
18. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16
19. Linjakumpu T, Hartikainen S, Klaukka T, et al. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002;55:809-17
20. Bjerrum L, Andersen M, Petersen G, et al. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003;21:153-8
21. Gold DT, Ettinger M, Gallagher R, et al. Medication burden among women with postmenopausal osteoporosis. Presented at the National Osteoporosis Foundation 6th International Symposium, Washington, DC, 6-10 April 2005
22. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-23
23. Schaffer SD, Yoon SJ. Evidence-based methods to enhance medication adherence. Nurse Pract 2001;26:44-54
24. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;9:S66-80
25. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106
26. van Beek E, Hoekstra M, van de Ruit M, et al. Structural requirements for bisphosphonate actions in vitro. J Bone Min Res 1994;9:1875-82
27. Russell RG, Rogers MJ, Frith JC, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Min Res 1999;14:53-65
28. Mühlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Min Res 1991;6:1003-11
29. Bauss F, Endele R, Besenfelder E, et al. Ibandronate: serum kinetics, tissue distribution and binding to bone following intravenous bolus injection. Calcif Tissue Int 2002;70:289-90 [abstract P-128]
30. Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004;15:423-33
31. Ravn P, Neugebauer G, Christiansen C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 2002;30:320-4
32. Bauss F, Lalla S, Endele R, et al. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheum 2002;29:2200-8
33. Riis BJ, Ise J, von Stein T, et al. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Min Res 2001;16:1871-8
34. Delmas PD, Recker RR, Chesnut CH 3rd, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8
35. McClung MR, Wasnich RD, Recker R, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Min Res 2004;19:11-8
36. Lewiecki M, Zaidi M, Drezner M, et al. Intermittent intravenous ibandronate injections are at least as effective as daily oral ibandronate: 1-year DIVA results. Menopause 2005;12:802
37. Delmas PD, Emkey R, Gilbride J, et al. Oral ibandronate has a similar gastrointestinal (GI) safety profile to placebo in patients with a history of GI disorders or receiving concomitant NSAIDS. Osteoporos Int 2003;14:S74 [abstract P267]
38. Adami S, Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf 1996;14:158-70
39. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87
40. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-9
41. Janssen van Doorn K, Neyns B, Van der Niepen P, et al. Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. Nephron 2001;89:467-8
42. Recker RR, Weinstein RS, Chesnut CH 3rd, et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 2004;15:231-7
43. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133-7
44. Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Min Res 2004;19:1241-9
45. Schimmer RC, Bauss F. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther 2003;25:19-34
46. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Min Res 2005;20:1315-22
47. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006;65:654-61 [Epub 8 Dec 2005]
48. Delmas P, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal osteoporosis: 1-year results from the DIVA study. Arthritis Rheum 2006 [in press]
49. Miller PD, Civitelli R, Zaidi M, et al. Efficacy of intravenous ibandronate injections in postmenopausal osteoporosis: DIVA 2-year findings. International Society for Clinical Densitometry annual meeting. San Diego, CA, 1-4 February 2006